Updated: June 16, 2026 CET Updated: June 16, 2026 CET Updated: April 08, 2025 CET Updated: June 16, 2026 CET Updated: May 19, 2025 CET
Nutr J 24 , 53 (2025)
By synthesizing these developments, this article aims to offer both theoretical insights and practical design principles for next-generation COF-based nanotherapeutics, ultimately supporting their translation into clinical applications
Since our immunohistochemical approach does not discriminate between enzymatically active and inactive forms of GPX1, monomeric and tetrameric forms and gene variants, caution also needs to be exercised in ascrib-ing a physiological role of GPX1 solely based on immunohistochemical approaches (Mohammedi et al
Supplementing with NAD+ can help restore these levels and support overall health
Moradi M, Mojtahedzadeh M, Mandegari A, Soltan-Sharifi MS, Najafi A, Khajavi MR, Hajibabayee M, Ghahremani MH